| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Testosterone | 81 | 2026 | 590 | 16.870 |
Why?
|
| Hypogonadism | 55 | 2026 | 324 | 13.980 |
Why?
|
| Erectile Dysfunction | 39 | 2026 | 195 | 12.500 |
Why?
|
| Hormone Replacement Therapy | 41 | 2026 | 214 | 9.980 |
Why?
|
| Prostatic Neoplasms | 32 | 2025 | 1398 | 5.750 |
Why?
|
| Androgens | 17 | 2025 | 267 | 4.450 |
Why?
|
| Penile Prosthesis | 11 | 2024 | 41 | 3.970 |
Why?
|
| Penile Implantation | 8 | 2024 | 25 | 3.570 |
Why?
|
| Cardiovascular Diseases | 22 | 2025 | 2098 | 2.550 |
Why?
|
| Prostatectomy | 18 | 2022 | 299 | 2.280 |
Why?
|
| Penile Induration | 5 | 2024 | 38 | 2.220 |
Why?
|
| Prostate-Specific Antigen | 12 | 2025 | 227 | 2.200 |
Why?
|
| Penile Erection | 15 | 2023 | 79 | 2.140 |
Why?
|
| Male | 137 | 2026 | 64486 | 2.140 |
Why?
|
| Urology | 5 | 2025 | 80 | 2.100 |
Why?
|
| Patient Satisfaction | 9 | 2025 | 451 | 1.500 |
Why?
|
| Libido | 4 | 2022 | 34 | 1.480 |
Why?
|
| Stem Cell Transplantation | 3 | 2024 | 229 | 1.480 |
Why?
|
| Humans | 141 | 2026 | 130403 | 1.460 |
Why?
|
| Penis | 9 | 2025 | 83 | 1.290 |
Why?
|
| Depression | 5 | 2026 | 1316 | 1.260 |
Why?
|
| Sexual Behavior | 8 | 2024 | 238 | 1.110 |
Why?
|
| Sexual Dysfunction, Physiological | 6 | 2025 | 83 | 1.090 |
Why?
|
| Sexual Health | 2 | 2025 | 19 | 1.050 |
Why?
|
| Urologists | 1 | 2025 | 11 | 0.900 |
Why?
|
| Holistic Health | 1 | 2025 | 12 | 0.890 |
Why?
|
| Middle Aged | 46 | 2025 | 28395 | 0.880 |
Why?
|
| Finasteride | 2 | 2022 | 16 | 0.880 |
Why?
|
| Microbial Collagenase | 1 | 2024 | 10 | 0.870 |
Why?
|
| Commerce | 1 | 2025 | 56 | 0.860 |
Why?
|
| Platelet-Rich Plasma | 1 | 2024 | 23 | 0.860 |
Why?
|
| Watchful Waiting | 1 | 2025 | 73 | 0.850 |
Why?
|
| Reproductive Health | 2 | 2024 | 48 | 0.850 |
Why?
|
| Androgen Antagonists | 2 | 2024 | 109 | 0.830 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2023 | 20 | 0.810 |
Why?
|
| Aged | 39 | 2025 | 20899 | 0.800 |
Why?
|
| Career Choice | 1 | 2025 | 165 | 0.800 |
Why?
|
| Health Care Costs | 3 | 2018 | 399 | 0.790 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2025 | 142 | 0.780 |
Why?
|
| Prosthesis Design | 4 | 2024 | 613 | 0.750 |
Why?
|
| Urinary Sphincter, Artificial | 1 | 2021 | 6 | 0.720 |
Why?
|
| Urinary Incontinence, Stress | 1 | 2021 | 32 | 0.710 |
Why?
|
| Adult | 37 | 2025 | 31125 | 0.690 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2021 | 14 | 0.690 |
Why?
|
| Fellowships and Scholarships | 1 | 2024 | 323 | 0.680 |
Why?
|
| Cystic Fibrosis | 1 | 2024 | 266 | 0.680 |
Why?
|
| Treatment Outcome | 25 | 2026 | 12852 | 0.670 |
Why?
|
| Polycythemia | 1 | 2020 | 45 | 0.640 |
Why?
|
| Telemedicine | 2 | 2024 | 511 | 0.630 |
Why?
|
| Eunuchism | 2 | 2022 | 7 | 0.630 |
Why?
|
| Surveys and Questionnaires | 12 | 2026 | 4015 | 0.620 |
Why?
|
| Retrospective Studies | 22 | 2026 | 17633 | 0.610 |
Why?
|
| Prostate | 4 | 2023 | 408 | 0.590 |
Why?
|
| Curriculum | 1 | 2024 | 784 | 0.590 |
Why?
|
| Fertility | 2 | 2018 | 256 | 0.580 |
Why?
|
| Botulinum Toxins, Type A | 3 | 2005 | 126 | 0.580 |
Why?
|
| Clomiphene | 1 | 2018 | 15 | 0.570 |
Why?
|
| North America | 7 | 2024 | 257 | 0.570 |
Why?
|
| Spinal Cord Injuries | 3 | 2007 | 272 | 0.550 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2017 | 51 | 0.530 |
Why?
|
| Aromatase Inhibitors | 1 | 2017 | 77 | 0.520 |
Why?
|
| Quality of Life | 8 | 2025 | 2070 | 0.500 |
Why?
|
| Societies, Medical | 5 | 2024 | 791 | 0.500 |
Why?
|
| Varicocele | 4 | 2010 | 60 | 0.490 |
Why?
|
| Prospective Studies | 12 | 2025 | 6447 | 0.470 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2017 | 250 | 0.470 |
Why?
|
| Abdominal Wall | 1 | 2015 | 26 | 0.460 |
Why?
|
| Semen Analysis | 2 | 2026 | 43 | 0.440 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2024 | 1250 | 0.440 |
Why?
|
| Postoperative Complications | 7 | 2024 | 3105 | 0.440 |
Why?
|
| Mass Screening | 2 | 2024 | 807 | 0.430 |
Why?
|
| Drug Implants | 5 | 2015 | 42 | 0.420 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2015 | 82 | 0.420 |
Why?
|
| Men's Health | 3 | 2024 | 22 | 0.420 |
Why?
|
| Medication Adherence | 1 | 2018 | 332 | 0.420 |
Why?
|
| Prostatic Hyperplasia | 3 | 2023 | 115 | 0.400 |
Why?
|
| Urinary Bladder | 2 | 2005 | 219 | 0.400 |
Why?
|
| Pandemics | 1 | 2021 | 1154 | 0.400 |
Why?
|
| Extracorporeal Shockwave Therapy | 2 | 2024 | 10 | 0.380 |
Why?
|
| Azoospermia | 3 | 2026 | 53 | 0.380 |
Why?
|
| Osteoporotic Fractures | 1 | 2012 | 30 | 0.370 |
Why?
|
| Carcinoma | 1 | 2015 | 284 | 0.370 |
Why?
|
| Comorbidity | 6 | 2018 | 1587 | 0.370 |
Why?
|
| United States | 17 | 2023 | 11826 | 0.370 |
Why?
|
| Registries | 9 | 2018 | 1603 | 0.360 |
Why?
|
| Urologic Diseases | 2 | 2023 | 42 | 0.360 |
Why?
|
| Klinefelter Syndrome | 1 | 2011 | 20 | 0.350 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2016 | 494 | 0.350 |
Why?
|
| Deficiency Diseases | 1 | 2011 | 9 | 0.340 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2011 | 54 | 0.340 |
Why?
|
| Heart Diseases | 1 | 2016 | 501 | 0.340 |
Why?
|
| Coitus | 2 | 2025 | 21 | 0.340 |
Why?
|
| Aging | 2 | 2016 | 1251 | 0.330 |
Why?
|
| Patient Compliance | 2 | 2011 | 466 | 0.330 |
Why?
|
| Impotence, Vasculogenic | 1 | 2010 | 7 | 0.330 |
Why?
|
| Public Health | 1 | 2012 | 272 | 0.320 |
Why?
|
| Nitric Oxide | 1 | 2013 | 467 | 0.320 |
Why?
|
| Aged, 80 and over | 12 | 2023 | 6773 | 0.310 |
Why?
|
| Risk Factors | 12 | 2021 | 10981 | 0.310 |
Why?
|
| Prevalence | 4 | 2018 | 2683 | 0.300 |
Why?
|
| Medicare | 5 | 2023 | 438 | 0.300 |
Why?
|
| Urologic Surgical Procedures, Male | 3 | 2019 | 29 | 0.300 |
Why?
|
| Cardiovascular System | 3 | 2021 | 99 | 0.300 |
Why?
|
| Female | 14 | 2026 | 70343 | 0.270 |
Why?
|
| Administration, Oral | 3 | 2025 | 695 | 0.270 |
Why?
|
| Rats, Sprague-Dawley | 6 | 2015 | 1111 | 0.270 |
Why?
|
| Disease Progression | 3 | 2025 | 2203 | 0.270 |
Why?
|
| Gels | 4 | 2023 | 65 | 0.260 |
Why?
|
| Operative Time | 3 | 2018 | 199 | 0.260 |
Why?
|
| Animals | 12 | 2025 | 33852 | 0.260 |
Why?
|
| Receptors, Epoprostenol | 1 | 2007 | 4 | 0.260 |
Why?
|
| Cell Proliferation | 1 | 2014 | 2467 | 0.260 |
Why?
|
| Databases, Factual | 3 | 2023 | 1222 | 0.260 |
Why?
|
| Linear Models | 3 | 2013 | 689 | 0.250 |
Why?
|
| Urinary Bladder, Overactive | 1 | 2007 | 29 | 0.250 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2007 | 39 | 0.250 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2022 | 749 | 0.240 |
Why?
|
| Behavior Therapy | 2 | 2023 | 271 | 0.240 |
Why?
|
| Image Cytometry | 1 | 2026 | 18 | 0.240 |
Why?
|
| Incidence | 5 | 2021 | 3346 | 0.240 |
Why?
|
| Urinary Incontinence | 1 | 2006 | 69 | 0.230 |
Why?
|
| Sensation | 1 | 2005 | 48 | 0.230 |
Why?
|
| Neurotoxins | 1 | 2005 | 45 | 0.230 |
Why?
|
| Muscle Strength | 1 | 2025 | 82 | 0.220 |
Why?
|
| Biomarkers | 3 | 2025 | 3395 | 0.220 |
Why?
|
| Rats | 6 | 2020 | 3374 | 0.220 |
Why?
|
| Mice, Nude | 2 | 2017 | 700 | 0.220 |
Why?
|
| Liver Function Tests | 1 | 2025 | 97 | 0.220 |
Why?
|
| Sexology | 1 | 2024 | 4 | 0.220 |
Why?
|
| Spermatogenesis | 2 | 2018 | 168 | 0.220 |
Why?
|
| Urethral Stricture | 1 | 2004 | 6 | 0.220 |
Why?
|
| Injections, Intralesional | 1 | 2024 | 45 | 0.220 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2025 | 149 | 0.220 |
Why?
|
| Estradiol | 3 | 2021 | 471 | 0.220 |
Why?
|
| Cosmetic Techniques | 1 | 2024 | 11 | 0.210 |
Why?
|
| Cell Line, Tumor | 3 | 2017 | 3702 | 0.210 |
Why?
|
| Spermatozoa | 1 | 2026 | 254 | 0.210 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2024 | 48 | 0.200 |
Why?
|
| Cholesterol, HDL | 1 | 2025 | 394 | 0.200 |
Why?
|
| Adenosine Triphosphate | 1 | 2004 | 263 | 0.200 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2023 | 1427 | 0.200 |
Why?
|
| Urinary Retention | 1 | 2023 | 18 | 0.200 |
Why?
|
| Flow Cytometry | 1 | 2026 | 769 | 0.200 |
Why?
|
| Alprostadil | 2 | 2016 | 20 | 0.200 |
Why?
|
| Neuromuscular Agents | 1 | 2004 | 64 | 0.200 |
Why?
|
| Time Factors | 4 | 2024 | 6183 | 0.200 |
Why?
|
| Neurocognitive Disorders | 1 | 2024 | 73 | 0.200 |
Why?
|
| Bayes Theorem | 1 | 2024 | 308 | 0.200 |
Why?
|
| Health Expenditures | 2 | 2016 | 134 | 0.190 |
Why?
|
| Patient Preference | 1 | 2025 | 149 | 0.190 |
Why?
|
| Blood Pressure | 2 | 2021 | 1337 | 0.190 |
Why?
|
| Triglycerides | 1 | 2025 | 605 | 0.190 |
Why?
|
| Drug Administration Schedule | 3 | 2013 | 728 | 0.190 |
Why?
|
| Cholesterol | 1 | 2025 | 541 | 0.190 |
Why?
|
| Receptors, Androgen | 3 | 2014 | 414 | 0.190 |
Why?
|
| Priapism | 1 | 2022 | 11 | 0.190 |
Why?
|
| Insurance Coverage | 1 | 2023 | 116 | 0.180 |
Why?
|
| Sildenafil Citrate | 2 | 2013 | 55 | 0.180 |
Why?
|
| Young Adult | 9 | 2024 | 9974 | 0.180 |
Why?
|
| Clinical Trials as Topic | 2 | 2025 | 1126 | 0.180 |
Why?
|
| Life Style | 1 | 2025 | 446 | 0.180 |
Why?
|
| Patient Education as Topic | 1 | 2025 | 454 | 0.170 |
Why?
|
| Biopsy | 1 | 2025 | 1239 | 0.170 |
Why?
|
| Artificial Intelligence | 1 | 2026 | 347 | 0.170 |
Why?
|
| Longitudinal Studies | 1 | 2025 | 1487 | 0.170 |
Why?
|
| Orchiectomy | 2 | 2017 | 49 | 0.160 |
Why?
|
| Traction | 1 | 2019 | 10 | 0.150 |
Why?
|
| Lung Transplantation | 1 | 2024 | 353 | 0.150 |
Why?
|
| Placenta | 1 | 2023 | 514 | 0.150 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 2 | 2016 | 34 | 0.150 |
Why?
|
| Regenerative Medicine | 1 | 2019 | 39 | 0.150 |
Why?
|
| Muscle, Skeletal | 1 | 2025 | 1003 | 0.150 |
Why?
|
| Neoplasm Grading | 2 | 2021 | 279 | 0.150 |
Why?
|
| Single-Blind Method | 1 | 2019 | 238 | 0.150 |
Why?
|
| Dementia | 1 | 2024 | 430 | 0.140 |
Why?
|
| Insurance, Health | 1 | 2019 | 139 | 0.140 |
Why?
|
| Infertility, Male | 3 | 2024 | 295 | 0.140 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2018 | 56 | 0.140 |
Why?
|
| Reoperation | 1 | 2021 | 830 | 0.140 |
Why?
|
| Lipids | 3 | 2023 | 562 | 0.140 |
Why?
|
| Anemia, Sickle Cell | 1 | 2022 | 324 | 0.140 |
Why?
|
| Chorionic Gonadotropin | 1 | 2018 | 77 | 0.140 |
Why?
|
| Estrogen Antagonists | 1 | 2018 | 92 | 0.140 |
Why?
|
| Hematocrit | 2 | 2021 | 105 | 0.140 |
Why?
|
| Organ Transplantation | 1 | 2020 | 168 | 0.140 |
Why?
|
| Double-Blind Method | 3 | 2023 | 1625 | 0.140 |
Why?
|
| Sex Hormone-Binding Globulin | 3 | 2014 | 50 | 0.140 |
Why?
|
| Caffeine | 1 | 2018 | 67 | 0.140 |
Why?
|
| Exercise | 1 | 2023 | 864 | 0.130 |
Why?
|
| Recovery of Function | 4 | 2022 | 440 | 0.130 |
Why?
|
| Liver | 1 | 2025 | 1802 | 0.130 |
Why?
|
| Pilot Projects | 2 | 2024 | 1452 | 0.130 |
Why?
|
| Biomarkers, Tumor | 2 | 2015 | 1608 | 0.130 |
Why?
|
| Gene Expression | 1 | 2021 | 1488 | 0.130 |
Why?
|
| Tumor Burden | 1 | 2017 | 240 | 0.120 |
Why?
|
| Diabetes Complications | 2 | 2015 | 197 | 0.120 |
Why?
|
| Dosage Forms | 1 | 2016 | 9 | 0.120 |
Why?
|
| Administration, Cutaneous | 2 | 2013 | 65 | 0.120 |
Why?
|
| Thrombosis | 1 | 2021 | 496 | 0.120 |
Why?
|
| Cohort Studies | 4 | 2020 | 5084 | 0.120 |
Why?
|
| Fasciotomy | 1 | 2015 | 25 | 0.120 |
Why?
|
| Follow-Up Studies | 4 | 2021 | 5204 | 0.120 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 313 | 0.110 |
Why?
|
| Age Distribution | 1 | 2016 | 424 | 0.110 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2015 | 157 | 0.110 |
Why?
|
| Endocrinology | 1 | 2017 | 128 | 0.110 |
Why?
|
| Heterografts | 1 | 2015 | 192 | 0.110 |
Why?
|
| Vulvodynia | 1 | 2014 | 4 | 0.110 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2014 | 18 | 0.110 |
Why?
|
| Luteinizing Hormone | 4 | 2015 | 129 | 0.110 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2015 | 40 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 2 | 2015 | 543 | 0.110 |
Why?
|
| History, 21st Century | 1 | 2015 | 256 | 0.110 |
Why?
|
| Heart Rate | 1 | 2017 | 574 | 0.110 |
Why?
|
| Reproduction | 1 | 2016 | 213 | 0.110 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 997 | 0.110 |
Why?
|
| Nanostructures | 1 | 2014 | 65 | 0.100 |
Why?
|
| History, 20th Century | 1 | 2015 | 360 | 0.100 |
Why?
|
| Case-Control Studies | 1 | 2021 | 3408 | 0.100 |
Why?
|
| Osteoporosis | 1 | 2015 | 133 | 0.100 |
Why?
|
| Androgen-Insensitivity Syndrome | 1 | 2013 | 26 | 0.100 |
Why?
|
| Postoperative Period | 3 | 2022 | 329 | 0.100 |
Why?
|
| Nitric Oxide Synthase | 2 | 2016 | 168 | 0.100 |
Why?
|
| Streptozocin | 1 | 2013 | 26 | 0.100 |
Why?
|
| Microspheres | 1 | 2013 | 67 | 0.100 |
Why?
|
| Bone Density | 1 | 2016 | 365 | 0.100 |
Why?
|
| Body Composition | 1 | 2016 | 549 | 0.100 |
Why?
|
| Disease Management | 1 | 2017 | 559 | 0.100 |
Why?
|
| Sulfones | 1 | 2013 | 71 | 0.100 |
Why?
|
| Education, Medical, Continuing | 1 | 2014 | 130 | 0.100 |
Why?
|
| Purines | 1 | 2013 | 114 | 0.100 |
Why?
|
| Health Surveys | 2 | 2011 | 255 | 0.100 |
Why?
|
| Adolescent | 5 | 2022 | 20731 | 0.100 |
Why?
|
| Decision Making | 1 | 2018 | 687 | 0.090 |
Why?
|
| Pregnancy | 2 | 2023 | 7423 | 0.090 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2013 | 186 | 0.090 |
Why?
|
| Risk Assessment | 2 | 2021 | 3692 | 0.090 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2013 | 140 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2013 | 427 | 0.090 |
Why?
|
| Tadalafil | 1 | 2011 | 4 | 0.090 |
Why?
|
| Hemoglobins | 1 | 2013 | 288 | 0.090 |
Why?
|
| Piperazines | 1 | 2013 | 268 | 0.090 |
Why?
|
| Polymorphism, Genetic | 1 | 2014 | 775 | 0.090 |
Why?
|
| Prosthesis-Related Infections | 1 | 2013 | 184 | 0.080 |
Why?
|
| Analysis of Variance | 1 | 2013 | 938 | 0.080 |
Why?
|
| Muscle Contraction | 2 | 2016 | 146 | 0.080 |
Why?
|
| Insulin Resistance | 1 | 2016 | 683 | 0.080 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 769 | 0.080 |
Why?
|
| Sexual Partners | 1 | 2011 | 79 | 0.080 |
Why?
|
| Logistic Models | 2 | 2018 | 1807 | 0.080 |
Why?
|
| Risk | 1 | 2012 | 731 | 0.080 |
Why?
|
| Chronic Disease | 2 | 2005 | 1231 | 0.080 |
Why?
|
| Body Mass Index | 2 | 2018 | 1682 | 0.080 |
Why?
|
| Cause of Death | 1 | 2012 | 505 | 0.080 |
Why?
|
| Health Status Indicators | 1 | 2010 | 111 | 0.080 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 1163 | 0.080 |
Why?
|
| Organ Size | 1 | 2010 | 423 | 0.080 |
Why?
|
| Program Development | 1 | 2010 | 178 | 0.080 |
Why?
|
| Pregnancy Outcome | 1 | 2012 | 620 | 0.080 |
Why?
|
| Mice | 2 | 2017 | 18180 | 0.070 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2009 | 6 | 0.070 |
Why?
|
| Patient Safety | 1 | 2014 | 440 | 0.070 |
Why?
|
| Vasodilator Agents | 1 | 2010 | 197 | 0.070 |
Why?
|
| Drug Monitoring | 1 | 2012 | 286 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2012 | 1501 | 0.070 |
Why?
|
| Age Factors | 4 | 2019 | 2835 | 0.070 |
Why?
|
| Evidence-Based Medicine | 3 | 2017 | 645 | 0.070 |
Why?
|
| Veins | 1 | 2009 | 96 | 0.070 |
Why?
|
| Health Status | 1 | 2010 | 367 | 0.070 |
Why?
|
| Preoperative Care | 1 | 2010 | 356 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 3805 | 0.070 |
Why?
|
| Laparoscopy | 2 | 2013 | 542 | 0.070 |
Why?
|
| Odds Ratio | 1 | 2010 | 1224 | 0.060 |
Why?
|
| Analgesics, Opioid | 1 | 2012 | 465 | 0.060 |
Why?
|
| Embolization, Therapeutic | 1 | 2009 | 230 | 0.060 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 4654 | 0.060 |
Why?
|
| Sex Factors | 1 | 2010 | 1333 | 0.060 |
Why?
|
| International Cooperation | 2 | 2017 | 156 | 0.060 |
Why?
|
| Minimal Clinically Important Difference | 1 | 2026 | 9 | 0.060 |
Why?
|
| Sperm Count | 1 | 2026 | 100 | 0.060 |
Why?
|
| Hand Strength | 1 | 2025 | 57 | 0.060 |
Why?
|
| Masturbation | 1 | 2025 | 2 | 0.060 |
Why?
|
| Constriction | 1 | 2025 | 46 | 0.060 |
Why?
|
| Sarcopenia | 1 | 2025 | 56 | 0.060 |
Why?
|
| Recurrence | 2 | 2009 | 1475 | 0.050 |
Why?
|
| Vascular Surgical Procedures | 1 | 2009 | 536 | 0.050 |
Why?
|
| Retreatment | 1 | 2004 | 87 | 0.050 |
Why?
|
| Urothelium | 1 | 2004 | 55 | 0.050 |
Why?
|
| Follicle Stimulating Hormone | 2 | 2015 | 182 | 0.050 |
Why?
|
| Random Allocation | 1 | 2025 | 416 | 0.050 |
Why?
|
| Transdermal Patch | 1 | 2023 | 7 | 0.050 |
Why?
|
| Phenylephrine | 1 | 2022 | 36 | 0.050 |
Why?
|
| Testosterone Congeners | 1 | 2022 | 14 | 0.050 |
Why?
|
| Equivalence Trials as Topic | 1 | 2021 | 21 | 0.050 |
Why?
|
| Isotretinoin | 1 | 2022 | 19 | 0.040 |
Why?
|
| Prosthesis Failure | 1 | 2022 | 151 | 0.040 |
Why?
|
| Monitoring, Ambulatory | 1 | 2021 | 55 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2021 | 298 | 0.040 |
Why?
|
| HIV Infections | 1 | 2013 | 2011 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2026 | 2298 | 0.040 |
Why?
|
| SEER Program | 1 | 2021 | 212 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2022 | 328 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 2 | 2016 | 1292 | 0.030 |
Why?
|
| Waist Circumference | 1 | 2018 | 95 | 0.030 |
Why?
|
| Critical Pathways | 1 | 2018 | 76 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2018 | 154 | 0.030 |
Why?
|
| Polypharmacy | 1 | 2017 | 37 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2021 | 1300 | 0.030 |
Why?
|
| Survival Rate | 1 | 2022 | 2134 | 0.030 |
Why?
|
| Premature Ejaculation | 1 | 2016 | 4 | 0.030 |
Why?
|
| Child | 3 | 2022 | 26159 | 0.030 |
Why?
|
| Nutrition Surveys | 1 | 2018 | 327 | 0.030 |
Why?
|
| Muscle, Smooth | 1 | 2016 | 114 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2023 | 992 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 1413 | 0.030 |
Why?
|
| Patient Participation | 1 | 2018 | 246 | 0.030 |
Why?
|
| Stroke | 1 | 2023 | 1054 | 0.030 |
Why?
|
| 2-Hydroxypropyl-beta-cyclodextrin | 1 | 2014 | 6 | 0.030 |
Why?
|
| beta-Cyclodextrins | 1 | 2014 | 12 | 0.030 |
Why?
|
| Luminescent Measurements | 1 | 2014 | 56 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 2017 | 469 | 0.030 |
Why?
|
| Trinucleotide Repeats | 1 | 2014 | 83 | 0.030 |
Why?
|
| Patient Admission | 1 | 2015 | 184 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2014 | 218 | 0.020 |
Why?
|
| Kinetics | 1 | 2014 | 1086 | 0.020 |
Why?
|
| Canada | 1 | 2013 | 321 | 0.020 |
Why?
|
| Robotics | 1 | 2013 | 102 | 0.020 |
Why?
|
| Body Weights and Measures | 1 | 2011 | 37 | 0.020 |
Why?
|
| Reference Values | 1 | 2012 | 679 | 0.020 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2011 | 41 | 0.020 |
Why?
|
| Personal Satisfaction | 1 | 2011 | 103 | 0.020 |
Why?
|
| Patient Selection | 1 | 2014 | 719 | 0.020 |
Why?
|
| Affect | 1 | 2011 | 165 | 0.020 |
Why?
|
| Alleles | 1 | 2014 | 1672 | 0.020 |
Why?
|
| Ligation | 1 | 2009 | 133 | 0.020 |
Why?
|
| Genotype | 1 | 2014 | 2607 | 0.020 |
Why?
|
| Hospital Costs | 1 | 2009 | 181 | 0.020 |
Why?
|
| Algorithms | 1 | 2015 | 1680 | 0.020 |
Why?
|
| Equipment Design | 1 | 2009 | 541 | 0.020 |
Why?
|
| Radiography | 1 | 2009 | 750 | 0.020 |
Why?
|
| Metabolic Syndrome | 1 | 2011 | 366 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2011 | 1103 | 0.020 |
Why?
|
| Obesity | 1 | 2011 | 2383 | 0.010 |
Why?
|